Cytiva Acquires Chromatography Resins Manufacturing Facility in Muskegon, Michigan
Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment.
Cytiva announced on July 13, 2022 that it had acquired a new manufacturing facility in Muskegon, MI. The new facility, a chromatography resins manufacturing site, is part of Cytiva and Pall Corporation's $1.5 billion capacity expansion investment, allowing Cytiva to expand its resin manufacturing beyond Sweden.
According to a company press release, Cytiva plans to renovate the site into a 168,000 ft² biomanufacturing center consisting of multiple buildings; it will house approximately 200 associates upon completion. With a planned construction start date in Q3 2022, manufacturing is expected to begin in 2026.
“When you’re looking to help provide global biotechnology solutions to the world, it requires you to be nimble and flexible,” said Emmanuel Ligner, Danaher Group Executive, president and CEO, Cytiva, in the press release. “By investing in Muskegon, Michigan, we will be closer to our North American customers, who are developing advanced biotherapeutics.”
Source: Cytiva
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
